EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development and refinement of the Clinical Global Impression of Improvement for Non-seizure Symptoms measure in Dravet syndrome and Lennox-Gastaut syndrome

J Scott Andrews, Drishti Shah, Alise Nacson, Tara Symonds, Sophie Hughes, Mahnaz Asgharnejad, Arturo Benitez, Lara Sams

Journal of Patient-Reported Outcomes · 2025

DOI: 10.1186/s41687-024-00829-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Patient-Reported Outcomes, 2025. Verfasst von J Scott Andrews und 7 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Development Center Americas, Inc., Cambridge, MA, USA. scott.andrews@takeda.com. Hauptthemen laut MEDLINE: Lennox Gastaut Syndrome, Epilepsies, Myoclonic, Patient Reported Outcome Measures. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Development Center Americas, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are rare, severe, childhood-onset developmental and epileptic encephalopathies characterized by treatment-resistant epilepsy and varying intellectual disability levels. Clinical outcome assessments (COAs) describe how patients feel, function, or survive, thus providing valuable information on a therapy’s efficacy and impact. Individuals with DS or LGS are heterogeneous, and many have limited verbal abilities and intellectual disability. Existing epilepsy-specific COA measures are unsuitable for DS and LGS clinical trials as many items demonstrate floor effects in these populations. As patients often cannot self-report symptoms, caregiver feedback on the measures’ relevance and understandability is critical when developing COAs to ensure their suitability for the intended population, and that caregivers can help clinicians complete the measures when necessary. Methodology We aimed to develop a novel clinician-reported outcomes measure, to be completed in consultation with caregivers at clinic visits, to assess non-seizure symptoms in individuals with DS or LGS using a Clinical Global Impression of Improvement (CGI–I) approach: the CGI-I Non-seizure Symptoms measure. A 13-item initial draft measure was reviewed by experts in a three-round Delphi panel to confirm each item’s relevance and refine descriptions, reduce overlap, and limit respondent burden.

Results

Following panel review, three items reached consensus (≥70% agreement of no revision required) and were included in the final measure: communication, alertness, and disruptive behaviors. To ensure caregivers can help clinicians complete the measure, and to establish levels of change in each item domain considered meaningful from their perspective, the three-item measure was cognitively debriefed with caregivers of individuals with DS or LGS. Caregivers showed that each item was understandable by describing their child using the descriptions provided in the measure and reported that items were relevant or important to assess in DS or LGS. Most caregivers reported that even a minimal change to their child’s condition in each domain would be meaningful to them and their child.

Conclusions

This CGI-I Non-seizure Symptoms measure represents relevant non-seizure outcomes considered important to individuals with DS or LGS and their families. The systematic development and refinement approach presented here supports its use in DS and LGS clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lennox Gastaut SyndromeEpilepsies, MyoclonicPatient Reported Outcome MeasuresHumansFemaleMaleChildCaregiversAdolescentChild, PreschoolAdultDelphi Technique

Stichwörter der Autor:innen

CGI-I Non-seizure SymptomsDravet syndromeEpilepsyLennox-Gastaut syndrome

Autor:innen und Institutionen

  • Takeda Development Center Americas, Inc., Cambridge, MA, USA. scott.andrews@takeda.com.
  • Takeda Development Center Americas, Inc., Cambridge, MA, USA. drishti.shah@takeda.com.
  • Clinical Outcomes Solutions, Chicago, IL, USA.
  • Clinical Outcomes Solutions, Folkestone, UK.
  • Takeda Development Center Americas, Inc., Cambridge, MA, USA.

Förderung

  • Takeda Development Center Americas, Inc.

Zitieren

APA

Andrews, J. S., Shah, D., Nacson, A., Symonds, T., Hughes, S., Asgharnejad, M., Benitez, A., & Sams, L. (2025). Development and refinement of the Clinical Global Impression of Improvement for Non-seizure Symptoms measure in Dravet syndrome and Lennox-Gastaut syndrome. Journal of Patient-Reported Outcomes. https://doi.org/10.1186/s41687-024-00829-2

Vancouver

Andrews JS, Shah D, Nacson A, Symonds T, Hughes S, Asgharnejad M, et al. Development and refinement of the Clinical Global Impression of Improvement for Non-seizure Symptoms measure in Dravet syndrome and Lennox-Gastaut syndrome. Journal of Patient-Reported Outcomes. 2025. doi:10.1186/s41687-024-00829-2

BibTeX
@article{Andrews2025,
  author = {Andrews, J Scott and Shah, Drishti and Nacson, Alise and Symonds, Tara and Hughes, Sophie and Asgharnejad, Mahnaz and Benitez, Arturo and Sams, Lara},
  title = {Development and refinement of the Clinical Global Impression of Improvement for Non-seizure Symptoms measure in Dravet syndrome and Lennox-Gastaut syndrome},
  journal = {Journal of Patient-Reported Outcomes},
  year = {2025},
  doi = {10.1186/s41687-024-00829-2}
}
Kostenlos starten →